Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx Safety Communication In Face Of Uncertainty, Multiple Risks, To Be Examined By FDA Panel

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Risk Communication Advisory Committee will delve into research on communicating uncertainty and how individuals perceive risk and seek information when confronted with multiple risks, during a June 29 meeting.

You may also be interested in...

Risk Communication Panel To Continue Discussion Of Uncertainty Messaging

FDA looking for more help from advisory committee on how much information about uncertainty to give as well as how best to communicate it to minority, uneducated groups.

Hydrocodone Gets Advisory Committee Review, Offering Congress A Scheduling Out

FDA announces the October meeting unusually early following legislative efforts to further restrict access to the opioid pain reliever due to abuse worries.

“Drug Facts” Box Not Ready For Prime Time, FDA Advisory Cmte. Says

FDA's Risk Communication Advisory Committee likes the concept of a standardized format in drug promotional labeling and print advertising, but remains concerned that different risk levels for different populations could negate its utility.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts